How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bortezomib-cyclophosphamide-thalidomide-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bortezomib, cyclophosphamide, thalidomide, dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bortezomib, cyclophosphamide, thalidomide, dexamethasone (Bortezomib, cyclophosphamide, thalidomide, dexamethasone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen (proteasome inhibitor + alkylating agent + immunomodulatory agent

phase 3 Combination chemotherapy regimen (proteasome inhibitor + alkylating agent + immunomodulatory agent + corticosteroid) Proteasome (bortezomib); DNA (cyclophosphamide); TNF-α pathway and cereblon (thalidomide); glucocorticoid receptor (dexamethasone) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bortezomib, cyclophosphamide, thalidomide, dexamethasone (Bortezomib, cyclophosphamide, thalidomide, dexamethasone) — Grupo de Estudos Multicentricos em Onco-Hematologia. This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing tumor necrosis factor, and providing immunomodulatory effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bortezomib, cyclophosphamide, thalidomide, dexamethasone TARGET	Bortezomib, cyclophosphamide, thalidomide, dexamethasone	Grupo de Estudos Multicentricos em Onco-Hematologia	phase 3	Combination chemotherapy regimen (proteasome inhibitor + alkylating agent + immunomodulatory agent + corticosteroid)	Proteasome (bortezomib); DNA (cyclophosphamide); TNF-α pathway and cereblon (thalidomide); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen (proteasome inhibitor + alkylating agent + immunomodulatory agent + corticosteroid) class)

Grupo de Estudos Multicentricos em Onco-Hematologia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bortezomib, cyclophosphamide, thalidomide, dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/bortezomib-cyclophosphamide-thalidomide-dexamethasone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab